Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 1082-1090

  Faber, Edgar ^a   Naušová, Jitka ^b   Jarošová, Marie ^a   Egorin, Merrill ^c   Holzerová, Milena ^a   Rožmanová, Šárka ^a   Marešová, Ivana ^a   Divoký, Vladimír ^b   Indrák, Karel ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Bcr Abl; Chronic myelogenous leukemia; CML; Imatinib mesylate; Intermittent therapy

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; CGP 74588; CRK LIKE PROTEIN; DRUG METABOLITE; HYDROXYUREA; IMATINIB; INTERFERON; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GENETIC DISORDER; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; LIVER TOXICITY; LONG TERM CARE; MALAISE; MALE; MUSCLE CRAMP; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT; STANDARD; THROMBOCYTOPENIA;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CYTOGENETICS; DRUG ADMINISTRATION SCHEDULE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PYRIMIDINES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33746300290     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600565057     Document Type: Article

References (30)

1. Guilhot, F and on behalf of the IRIS Study Group. (2004) Sustained durability of responses plus high rate of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia treated with imatinib therapy: Update from the IRIS study Blood, 104, pp. 10a.
2. Hochhaus, A and Kreil, S and Corbin, A and La Rosée, P and Muller, M and Lahaye, T and et al. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia, 16, pp. 2190-2196.
3. O'Brien, S and Guilhot, F and Larson, R and Gathmann, I and Baccarani, M and Carvantes, F and (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Eng J Med, 348, pp. 994-1004.
4. Kantarjian, H and Cortes, J and O'Brien, S and Luthra, R and Giles, F and Verstovsek, S and et al. (2004) Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α Blood, 104, pp. 1979-1988.
5. Talpaz, M and Silver, R and Druker, B and Goldman, J and Gambacorti-Passerini, C and Guilhot, F and et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study Blood, 99, pp. 1928-1937.
6. Sawyers, C and Hochhaus, A and Feldman, E and Goldman, J and Miller, C and Ottmann, O. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study Blood, 99, pp. 3530-3539.
7. Sumi, M and Tauchi, T and Shimamoto, T and Sshida, G and Nakajima, A and Ito, Y and et al. (2002) Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy Rinsho Ketsueki, 43, pp. 868-870.
8. Quintas-Cardama, A and Kantarjian, H and O'Brien, S and Garcia-Manero, G and Rios, M and Talpaz, M and et al. (2004) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia Cancer, 100, pp. 2592-2597.
9. Marin, D and Marktel, S and Foot, N and Bua, M and Goldman, J and Apperley, J. (2003) Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate Haematologica, 88, pp. 227-229.
10. Sokal, J and Cox, E and Baccarani, M and Tura, S and Gomez, G and Robertson, J and et al. (1984) Prognostic discrimination in 'good-risk' chronic granulocytic leukemia Blood, 63, pp. 789-799.
11. Hasford, J and Pfirrmann, M and Hehlmann, R and Allan, N and Baccarani, M and Kluin-Nelemans, J and et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa J Nat Cancer Inst, 90, pp. 850-858.
12. The Italian Cooperative Study Group on chronic myeloid leukemia. (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia N Eng J Med, 330, pp. 820-825.
13. Chomczynski, P and Sacchi, N. (1987) Single-step method of RNA isolation by quanidium thiocyanate-phenol-chloroform extraction Anal Biochem, 162, pp. 156-159.
14. Gabert, J and Beillard, E and van der Velden, V and Bi, W and Grimwade, D and Pallisgaard, N and et al. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for rezidual disease detection in leukemia - a Europe against cancer program Leukemia, 17, pp. 2318-2357.
15. Parise, R and Ramanathan, R and Hayes, M and Egorin, M. (2003) A sensitive high-performance liquid chromatography-mass spectrometry assay for quantitation of imatinib and it's main metabolite (CGP 74588) in plasma J Chromatol B, 791, pp. 39-44.
16. Yeh, K and Kwan, K. (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation J Pharmacokinetics Biopharm, 6, pp. 79-98.
17. Rocci, M, Jr and Jusko, W. (1983) LAGRAN program in area and moments in pharmacokinetic analysis Comput Programs Biomed, 16, pp. 203-216.
18. Peng, B and Hayes, M and Resta, D and Racine-Poon, A and Druker, B and Talpaz, M and et al. (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol, 22, pp. 935-942.
19. Horikoshi, A and Takei, K and Sawada, S. (2003) Effects of lower dose of imatinib to CML patients Leuk Res, 27, pp. 1167.
20. Tanvetyanon, T and Nand, S. (2003) Overcoming recurrent cutaneous reactions from imatinib use by once-weekly dosing Ann Pharmacother, 37, pp. 1818-1820.
21. Zipin, D and Savage, D. (2004) Reduced dose imatinib mesylate therapy for chronic myeloid leukemia Leuk Lymphoma, 45, pp. 2363-2364.
22. Cortes, J and Giles, F and O'Brien, S and Thomas, D and Garcia-Manero, G and Beth Rios, M and et al. (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α Blood, 102, pp. 83-86.
23. Cortes, J and O'Brien, S and Kantarjian, H. (2004) Discontinuation of imatinib therapy after achieving a molecular response Blood, 104, pp. 2204-2205.
24. Hochhaus, A and La Rosée, P. (2004) Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance Leukemia, 18, pp. 1321-1331.
25. Liu, N and O'Brien, S. (2002) Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia Leuk Lymphoma, 43, pp. 2413-2415.
26. Higashi, T and Tsukada, J and Kato, C and Iwashige, A and Mizobe, T and Machida, S and et al. (2004) Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases Am J Hematol, 76, pp. 275-278.
27. Murase, K and Matsunaga, T and Takeuchi, N and Fujimi, A and Takimoto, R and Terui, T and et al. (2004) Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib Rinsho Ketsueki, 45, pp. 1028-1032.
28. Desplat, V and Belloc, F and Lagarde, V and Boyer, C and Melo, J and Reiffers, J and et al. (2005) Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines Cancer, 103, pp. 102-110.
29. Sneed, T and Kantarjian, H and Talpaz, M and O'Brien, S and Rios, M and Bekele, B. (2004) The significance of myelosupression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase Cancer, 100, pp. 116-121.
30. Wang, J. (2000) Regulation of cell death by the Abl tyrosine kinase Oncogene, 19, pp. 5643-5650.